Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease

Alessandro Zaccagna, Alberto Bertone, Paolo Puiatti, Franco Picciotto, Tatiana Sprujevnik, Renato Santucci, Francesco Paolo Rossini

Research output: Contribution to journalArticle


Here we report a case of Pyoderma gangrenosum (PG) associated with Crohn's disease successfully treated with infliximab, The efficacy of this drug in many inflammatory diseases has already been reported, but its use in PG has only been seen in very few cases. Our study confirms that this therapy is a valid alternative solution for treating PG, which is often unresponsive to conventional therapies.

Original languageEnglish
Pages (from-to)258-260
Number of pages3
JournalEuropean Journal of Dermatology
Issue number3
Publication statusPublished - May 2003



  • Crohn's disease
  • Infliximab
  • Neutrophilic dermatoses
  • Pyoderma gangrenosum
  • Therapy
  • Tumor-necrosis-factor-alpha

ASJC Scopus subject areas

  • Dermatology

Cite this